Clarity by Design
The iRhythm® cardiac monitoring service combines thoughtfully engineered devices, intelligent algorithms, and expert clinical review.
From seamless patient wear to physician-ready reports, every element works together to deliver precise answers when they matter most.
Clarity That Drives Confidence
Through advanced monitoring technology, intelligent algorithms, and expert clinical review, iRhythm delivers meaningful, actionable data — helping clinicians diagnose with greater confidence from the start.1
Improved wear experience
Zio ECG monitors are designed to be comfortable2-3 and easy to wear3-4 for better patient satisfaction and compliance2-3
Outstanding patient compliance
Near-perfect patient compliance5 generates high-quality, actionable data1
Remarkable clinical outcomes
Compared to other monitoring services, including long-term continuous monitors (LTCMs), the iRhythm LTCM service is a continuous, uninterrupted10 cardiac monitor associated with:
More than a monitor
The iRhythm monitoring service delivers clarity at every step — from the moment a Zio® ECG monitor is prescribed and worn, through advanced AI-assisted analysis and expert review, to physician-ready, clinically actionable reports. With intuitive tools like the ZioSuite® portal, seamless EHR integration, and patient-centric support via the MyZio® app, the iRhythm monitoring service helps simplify workflows and bring meaningful insight to your practice.
Incredible 99% physician agreement with end-of-wear reports
The iRhythm monitoring service combines the first FDA-cleared, deep-learned algorithm verified by QCTs12-15 to generate reports with 99% physician agreement,16 which can lead to an accurate and more timely diagnosis.1,6-10
Keep reading
- Data on file. iRhythm Technologies, 2023.
- Zio Monitor Instructions for Use. iRhythm Technologies.
- Battisti et al. Abstract 4141717: Feasibility of point-of-wear patient satisfaction surveys to validate patient-centered product enhancements: results from over 300,000 patients for long-term ambulatory cardiac monitoring. Circulation. 2024;150:A4141717. doi:10.1161/circ.150.suppl_1.4141717. https://www.ahajournals.org/doi/abs/10.1161/circ.150.suppl_1.4141717
- Data on file. iRhythm Technologies, 2024
- Data on file. iRhythm Technologies, 2022.
- Reynolds et al. Comparative effectiveness and healthcare utilization for ambulatory cardiac monitoring strategies in Medicare beneficiaries. Am Heart J. 2024;269:2534. https://doi.org/10.1016/j.ahj.2023.12.002
- A specified arrhythmia refers to an arrhythmia encounter diagnosis as per Hierarchical Condition Categories (HCC) 96.
- The study is based on the previous generation Zio XT device data. The devices used in the Zio LTCM monitoring service are deemed substantially equivalent. Additional data on file.
- Zio LTCM service refers to Zio XT and Zio monitor service.
- The Zio service facilitates a diagnosis as determined by a physician.
- ZioSuite Clinical Reference Manual. iRhythm Technologies.
- Data on file. iRhythm Technologies, 2020.
- Hannun et al. Cardiologist-level arrhythmia detection and classification in ambulatory electrocardiograms using a deep neural network. Nat Med. 2019;25:65-69. https://doi.org/10.1038/s41591-018-0268-3
- Deep learned algorithm is only available in the United States, the European Union, Switzerland, the United Kingdom, and Japan.
- FDA 510K clearance, CE mark, UKCA mark, and PMDA-approval.
- 99% of physicians agree with the comprehensive end-of-wear report. Based on a review of all online Zio XT, Zio monitor, and Zio AT end-of-wear reports. Data on file. iRhythm Technologies, 2023.
- Data on file. iRhythm Technologies. 2026.
WEB0001.03